A new era for the treatment of multiple sclerosis - A setback in the enthusiasm when a highly effective drug showed severe side-effects;Ny era för MS-behandling: Men svårt avbräck i entusiasmen - Högeffektivt medel gav allvarliga bieffekter

Lakartidningen

Volumn 103, Issue 17, 2006, Pages 1282-1283

  Olsson, Tomas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NATALIZUMAB;

ARTICLE; DRUG APPROVAL; HUMAN; MULTIPLE SCLEROSIS;

ANTIBODIES, MONOCLONAL; DRUG APPROVAL; HUMANS; MULTIPLE SCLEROSIS;

EID: 33646687713     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (3)

1. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
2. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiples sclerosis. N Engl J Med. 2006;354(9):911-23.
3. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924-33.